Cargando…

Nanoparticle-Based Peptide Vaccines

The use of peptide antigens for vaccination, compared with traditional vaccines, has advantages such as purity and low risk of adverse effects and disadvantages such as weak immunogenicity and necessitates administration with an adjuvant. To benefit from these advantages and at the same time overcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Y., Taguchi, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152328/
http://dx.doi.org/10.1016/B978-0-323-39981-4.00008-7
_version_ 1783521454359314432
author Fujita, Y.
Taguchi, H.
author_facet Fujita, Y.
Taguchi, H.
author_sort Fujita, Y.
collection PubMed
description The use of peptide antigens for vaccination, compared with traditional vaccines, has advantages such as purity and low risk of adverse effects and disadvantages such as weak immunogenicity and necessitates administration with an adjuvant. To benefit from these advantages and at the same time overcome the disadvantages, a wide variety of nanoparticles are being actively studied for the development of peptide-based vaccines, in which the antigen either is loaded on the particle surface or is present within the particle. In this chapter, we will provide a brief overview of synthetic peptide–based vaccine research, with special attention on multiple antigen-presenting peptide vaccines. Further, we will introduce the current approaches for the development of nanoparticle-based peptide vaccines, which use well-characterized synthetic peptide antigens with facile chemical modifications (eg, attachment of lipid chain(s) or self-assembling peptide sequences). These modifications can be employed to induce peptide self-assembly into nanoparticles, which present multiple copies of peptide antigens on their surface.
format Online
Article
Text
id pubmed-7152328
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-71523282020-04-13 Nanoparticle-Based Peptide Vaccines Fujita, Y. Taguchi, H. Micro and Nanotechnology in Vaccine Development Article The use of peptide antigens for vaccination, compared with traditional vaccines, has advantages such as purity and low risk of adverse effects and disadvantages such as weak immunogenicity and necessitates administration with an adjuvant. To benefit from these advantages and at the same time overcome the disadvantages, a wide variety of nanoparticles are being actively studied for the development of peptide-based vaccines, in which the antigen either is loaded on the particle surface or is present within the particle. In this chapter, we will provide a brief overview of synthetic peptide–based vaccine research, with special attention on multiple antigen-presenting peptide vaccines. Further, we will introduce the current approaches for the development of nanoparticle-based peptide vaccines, which use well-characterized synthetic peptide antigens with facile chemical modifications (eg, attachment of lipid chain(s) or self-assembling peptide sequences). These modifications can be employed to induce peptide self-assembly into nanoparticles, which present multiple copies of peptide antigens on their surface. 2017 2016-10-07 /pmc/articles/PMC7152328/ http://dx.doi.org/10.1016/B978-0-323-39981-4.00008-7 Text en Copyright © 2017 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Fujita, Y.
Taguchi, H.
Nanoparticle-Based Peptide Vaccines
title Nanoparticle-Based Peptide Vaccines
title_full Nanoparticle-Based Peptide Vaccines
title_fullStr Nanoparticle-Based Peptide Vaccines
title_full_unstemmed Nanoparticle-Based Peptide Vaccines
title_short Nanoparticle-Based Peptide Vaccines
title_sort nanoparticle-based peptide vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152328/
http://dx.doi.org/10.1016/B978-0-323-39981-4.00008-7
work_keys_str_mv AT fujitay nanoparticlebasedpeptidevaccines
AT taguchih nanoparticlebasedpeptidevaccines